Economic analysis of the use of drug-eluting stents from the perspective of Belgian health care

Acta Cardiologica

Volumn 62, Issue 4, 2007, Pages 355-365

  Mahieu, Joris ^a,c   De Ridder, Annemieke ^a   De Graeve, Diana ^a   Vrints, Chris ^b   Bosmans, Johan ^b  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^c NONE   (Belgium)

Author keywords

Belgium; Drug eluting; Economic analysis; Restenosis; Stents

Indexed keywords

PACLITAXEL; RAPAMYCIN;

ARTICLE; BELGIUM; COST BENEFIT ANALYSIS; DEVICE; DRUG ELUTING STENT; HEALTH CARE; HIGH RISK POPULATION; HUMAN; IN-STENT RESTENOSIS; INTERMETHOD COMPARISON; LONG TERM CARE; REVASCULARIZATION; RISK ASSESSMENT;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; BELGIUM; CORONARY ARTERY BYPASS; CORONARY RESTENOSIS; COST-BENEFIT ANALYSIS; DRUG-ELUTING STENTS; FOLLOW-UP STUDIES; HUMANS; METALS; PACLITAXEL; PROSTHESIS DESIGN; REOPERATION; RESEARCH DESIGN; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SIROLIMUS; TREATMENT OUTCOME;

EID: 34548177049     PISSN: 00015385     EISSN: None     Source Type: Journal    
DOI: 10.2143/AC.62.4.2022279     Document Type: Article

References (15)

1. Van der Hoeven BL, Pires NMM, Warda HM, Oemrawsingh PV, van Vlijmen BJM, Quax PHA, Schalij MJ, van der Wall EE, Jukema JW. Drug-eluting stents: results, promises and problems. Int J Cardiol 2005; 99: 9-17.
2. Sousa EJ, Serruys PW, Costa MA. New frontiers in cardiology: Drug-eluting stents: Part I. Circulation 2003; 107: 2273-9.
3. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, Popma JJ, Russell ME. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation 2004; 109: 1942-7.
4. Shafiq N, Malhotra S, Pandhi P, Grovera A, Uboweja A. A meta-analysis of clinical trials of paclitaxel- and sirolimus-eluting stents in patients with obstructive coronary artery disease. Br J Clin Pharmacol 2004; 59: 94-101.
5. Katritsis DG, Karvouni E, Ioannidis JPA. Meta-analysis comparing drug-eluting stents with bare metal stents. Am J Cardiol 2005; 95: 640-3.
6. Drug-Eluting Stent Update, Endovascular Today, May 2004, p. 28-29. Online available at: http://www.evtodayarchive.com/etart/et0504/et0504_update5. qxd%2040.pdf
7. Silber S. Which parameter should be chosen as primary endpoint for randomized drug-eluting stent studies? J Interv Cardiol 2004; 17: 376-7.
8. Holmes DR, Leon MB, Moses JW, Popma JJ, Cutlip D, Fitzgerald PJ, Brown C, Fischell T, Wong SC, Midei M, Snead D, Kuntz RE. Analysis of 1-year clinical outcomes in the SIRIUS trial. Circulation 2004; 109: 634-40.
9. Cohen DJ, Bakhai A, Shi C, Githiora L, Lavelle T, Berezin RH, Leon MB, Moses JW, Carrozza JP, Zidar JP, Kuntz RE. Cost-effectiveness of Sirolimus-eluting stents for treatment of complex coronary stenoses. Circulation 2004; 110: 508-14.
10. Mahadeva H. Drug-eluting stents: Cypher vs. Taxus, IMS Health, last review on February 25, 2005, available online at: http://www.ims-global. com/insight/news_story/0502/news_story_050225.htm
11. Simpson SD. The stent wars continue, last review on March 8, 2005. Online available online at: http://www.fool.com/News/mft/2005/mft05030815.htm
12. Snider K. Medtronic stent to cut profit growth. China Daily, March 7, 2005. Online available at: http://www.chinadaily.com.cn/english/doc/2005-03/ 07/content_422367.htm
13. Wood S. Studies linking drug-eluting stents to increased mortality/MI spark impassioned pleas for reason and calls for calm. The Heart, September 3, 2006. Online available at: http://www.theheart.org/article/736863. do
14. World Health Organisation (WHO), 2005(b), Prevalence of diabetes worldwide. Online available on http://www.who.int/diabetes/facts/ world_figures/en/
15. Federaal Kenniscentrum voor de Gezondheidszorg, 2006, Voorlopige richtlijnen voor farmaco-economisch onderzoek in België. KCE Reports 2006: 28(a). Online available at: http://kce.fgov.be/index_nl.aspx?ID=0&SGREF= 5264&CREF=6516 [in Dutch].